Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002329 · ClinicalTrials.gov registry record · Phase 1
A Study of MDL 28,574A in HIV-Infected Patients
A Phase 1 study, sponsored by Hoechst Marion Roussel.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002329: Completed Phase 1 study, sponsored by Hoechst Marion Roussel.
NCT00002329 is a Phase 1 study that has completed, run by Hoechst Marion Roussel. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002329, a Phase 1 study, has completed, sponsored by Hoechst Marion Roussel.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
To characterize the safety profile of MDL 28574A following both acute and subchronic dosing in HIV-positive patients. To determine the MTD of both acute and subchronic doses of this drug when administered as oral solution. To determine the pharmacokinetic profile of MDL 28574A and castanospermine (from which MDL 28574A is derived) following both acute and subchronic dosing.
Interventions
- DRUG Celgosivir hydrochloride
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
What the finished NCT00002329 record still lists
NCT00002329 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Celgosivir hydrochloride is the first listed.
NCT00002329 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002329 about?
NCT00002329 is a clinical study titled "A Study of MDL 28,574A in HIV-Infected Patients". To characterize the safety profile of MDL 28574A following both acute and subchronic dosing in HIV-positive patients. To determine the MTD of both acute and subchronic doses of this drug when administered as oral solution. To determine the pharmacokinetic profile of MDL 28574A and castanospermine (f...
What is the current status of trial NCT00002329?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00002329?
The interventions under investigation include: Celgosivir hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002329?
This trial is sponsored by Hoechst Marion Roussel, which has 4 total clinical trials registered on ClinicalTrials.gov.